AR083591A1 - Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona - Google Patents
Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-onaInfo
- Publication number
- AR083591A1 AR083591A1 ARP110103993A ARP110103993A AR083591A1 AR 083591 A1 AR083591 A1 AR 083591A1 AR P110103993 A ARP110103993 A AR P110103993A AR P110103993 A ARP110103993 A AR P110103993A AR 083591 A1 AR083591 A1 AR 083591A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrimidin
- bis
- amino
- oxobutil
- hydropired
- Prior art date
Links
- UUDLQDCYDSATCH-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.OC(=O)C(O)C(O)C(O)=O UUDLQDCYDSATCH-UHFFFAOYSA-N 0.000 title abstract 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente se refiere al 1,5 hidrato de tartrato de 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona, un proceso para prepararlo, y una composición farmacéutica para inhibir la DPP-IV, que comprende dicho compuesto como componente activo.Reivindicación 1: 1,5 hidrato de sal de tartrato de 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidro-pirido [3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona, caracterizado porque tiene un contenido de agua en el rango que oscila entre 3,5 y 5,5 %.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100107868 | 2010-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083591A1 true AR083591A1 (es) | 2013-03-06 |
Family
ID=45995015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103993A AR083591A1 (es) | 2010-11-01 | 2011-10-28 | Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8859567B2 (es) |
| EP (1) | EP2635580B1 (es) |
| JP (1) | JP6193762B2 (es) |
| KR (1) | KR101446789B1 (es) |
| CN (1) | CN103189375B (es) |
| AP (1) | AP3287A (es) |
| AR (1) | AR083591A1 (es) |
| AU (1) | AU2011324253B2 (es) |
| BR (1) | BR112013010586A2 (es) |
| CA (1) | CA2814357C (es) |
| CL (1) | CL2013001137A1 (es) |
| CO (1) | CO6710945A2 (es) |
| DO (1) | DOP2013000090A (es) |
| EA (1) | EA024679B1 (es) |
| EC (1) | ECSP13012599A (es) |
| GE (1) | GEP20156218B (es) |
| IL (1) | IL225808A (es) |
| MA (1) | MA34625B1 (es) |
| MX (1) | MX341584B (es) |
| MY (1) | MY156428A (es) |
| NZ (1) | NZ609644A (es) |
| PE (3) | PE20140392A1 (es) |
| PH (1) | PH12013500685A1 (es) |
| SG (1) | SG189931A1 (es) |
| TW (1) | TWI519533B (es) |
| UA (1) | UA106445C2 (es) |
| UY (1) | UY33696A (es) |
| WO (1) | WO2012060590A2 (es) |
| ZA (1) | ZA201302646B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5066175B2 (ja) | 2006-03-31 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| MY180726A (en) | 2013-03-06 | 2020-12-08 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
| PH12023550900A1 (en) * | 2020-10-13 | 2024-03-04 | Lg Chemical Ltd | Oral combined formulation including gemigliptin and dapagliflozin and preparation method therefor |
| KR20250137744A (ko) | 2024-03-11 | 2025-09-19 | 엠에프씨 주식회사 | 제미글립틴의 신규 결정형 및 이의 제조방법 |
| KR20250147756A (ko) | 2024-03-27 | 2025-10-14 | 엠에프씨 주식회사 | 신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법 |
| KR20250155700A (ko) | 2024-04-24 | 2025-10-31 | 주식회사 다산제약 | 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물 |
| CN119285630B (zh) * | 2024-09-05 | 2025-05-27 | 安徽峆一药业股份有限公司 | 一种吉格列汀草酸盐及其晶型、制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE451369T1 (de) | 2002-07-15 | 2009-12-15 | Merck & Co Inc | Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes |
| EP1592689A4 (en) * | 2003-01-31 | 2008-12-24 | Merck & Co Inc | 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| TWI357902B (en) * | 2005-04-01 | 2012-02-11 | Lg Life Science Ltd | Dipeptidyl peptidase-iv inhibiting compounds, meth |
-
2011
- 2011-10-27 TW TW100139075A patent/TWI519533B/zh active
- 2011-10-28 AR ARP110103993A patent/AR083591A1/es unknown
- 2011-10-28 KR KR1020110111672A patent/KR101446789B1/ko active Active
- 2011-10-28 UY UY0001033696A patent/UY33696A/es unknown
- 2011-10-31 WO PCT/KR2011/008186 patent/WO2012060590A2/en not_active Ceased
- 2011-10-31 PE PE2013000904A patent/PE20140392A1/es not_active Application Discontinuation
- 2011-10-31 SG SG2013029434A patent/SG189931A1/en unknown
- 2011-10-31 EA EA201390644A patent/EA024679B1/ru unknown
- 2011-10-31 CN CN201180052217.1A patent/CN103189375B/zh active Active
- 2011-10-31 AU AU2011324253A patent/AU2011324253B2/en active Active
- 2011-10-31 AP AP2013006866A patent/AP3287A/xx active
- 2011-10-31 GE GEAP201113077A patent/GEP20156218B/en unknown
- 2011-10-31 UA UAA201305462A patent/UA106445C2/ru unknown
- 2011-10-31 MA MA35861A patent/MA34625B1/fr unknown
- 2011-10-31 NZ NZ609644A patent/NZ609644A/en active IP Right Revival
- 2011-10-31 BR BR112013010586A patent/BR112013010586A2/pt not_active Application Discontinuation
- 2011-10-31 MY MYPI2013001318A patent/MY156428A/en unknown
- 2011-10-31 CA CA2814357A patent/CA2814357C/en active Active
- 2011-10-31 US US13/879,571 patent/US8859567B2/en active Active
- 2011-10-31 PH PH1/2013/500685A patent/PH12013500685A1/en unknown
- 2011-10-31 JP JP2013536534A patent/JP6193762B2/ja active Active
- 2011-10-31 PE PE2018000088A patent/PE20180464A1/es unknown
- 2011-10-31 EP EP11838195.3A patent/EP2635580B1/en not_active Revoked
- 2011-10-31 PE PE2023001454A patent/PE20240220A1/es unknown
- 2011-10-31 MX MX2013004776A patent/MX341584B/es active IP Right Grant
-
2013
- 2013-04-11 ZA ZA2013/02646A patent/ZA201302646B/en unknown
- 2013-04-17 IL IL225808A patent/IL225808A/en active IP Right Grant
- 2013-04-22 DO DO2013000090A patent/DOP2013000090A/es unknown
- 2013-04-25 CL CL2013001137A patent/CL2013001137A1/es unknown
- 2013-04-30 CO CO13108961A patent/CO6710945A2/es unknown
- 2013-05-02 EC ECSP13012599 patent/ECSP13012599A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083591A1 (es) | Hidrato de tartrato de 1-{(2s)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6h)-il]-4-oxobutil)-5,5-difluoro-piperidin-2-ona | |
| CL2012000248A1 (es) | Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina. | |
| AR084551A1 (es) | COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DUAL DE mTOR/CINASA PI3 | |
| UY35115A (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| CL2014000343A1 (es) | Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor. | |
| UY34870A (es) | Cristales de sal | |
| CL2013002688A1 (es) | Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer. | |
| ECSP14030098A (es) | Formas cristalinas de un modulador del receptor androgénico | |
| GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
| CL2013002166A1 (es) | Compuesto correspondiente a la sal de magnesio del acido (s)-alfa-etoxi-4-[2-metil-5-[4-metiltiofenil-1h-pirrol-1-il]etoxi]bencenpropanoico; composicion farmaceutica que lo comprende; y uso para el tratamiento de lipodistrofia. | |
| BRPI1006869A2 (pt) | estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil | |
| BR112014029708A2 (pt) | composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina | |
| MY159492A (en) | Solid pharmaceutical formulation with delayed release | |
| BR112016008994A2 (pt) | Compostos de pirido[2,3-d]pirimidin-4-ona como inibidores de tanquirase | |
| PE20142358A1 (es) | Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa | |
| CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
| BR112012024239A2 (pt) | composição para tratamento de trombocitemia essencial | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| TN2013000161A1 (en) | Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
| BR112015004127A2 (pt) | sais de composto benzotiazolona como agonista de beta-2-adrenorreceptor | |
| UY31601A1 (es) | Nueva sal derivada de 7-metil-6-{2-[4-(2-metil-5-quinolinil)-1-piperazinil]etil}-4,5-dihidroimidazo[1,5-a]-quinolin-3-carboxamida. | |
| AR052589A1 (es) | Tetrahidrato acido de la sal de arginina de benzoquinolizina -2-carboxilico | |
| CL2011001916A1 (es) | Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |